Green analytical methods based on chemometrics and UV spectroscopy for the simultaneous estimation of empagliflozin and linagliptin

Empagliflozin and Linagliptin are used together as a fixed dose combination for type II diabetes. It is available as fixed-dose combination tablets in 10:5 and 25:5 (amount in milligrams) of EMPA and LINA, respectively. Two simple chemometrics methods were developed, namely ratio mean centering method and difference between adjacent data point method for the simultaneous estimation of Empagliflozin and Linagliptin in marketed formulation. For the data processing, a simple software program written with Python and MATPLOTLIB was used. Beer's law is valid in the range of 2–10 µg/ml for Empagliflozin and Linagliptin. The assay results obtained for the marketed formulation were found to be in the range of 98.08 - 99.25% for Empagliflozin and 98.40 - 99.86% for Linagliptin by Ratio mean centering method: Assay results were in the range of 99.90 - 100.92% for Empagliflozin and 99.12 - 102.40% for Linagliptin by Difference between adjacent data point method. The new methods can be successfully employed for the assay of the marketed formulation. To the best of our understanding, this is the first reported green method for analysing Empagliflozin and Linagliptin.